GlaxoSmithKline Pharmaceuticals Financial Statements
Quarterly
Yearly
| Particulars | Mar '21 | Jun '21 | Sep '21 | Dec '21 | Mar '22 |
|---|---|---|---|---|---|
| Revenue | 540.49 | 789.99 | 934.12 | 815.92 | 809.63 |
| Expenses | 602.96 | 656.03 | 693.50 | 653.90 | 620.26 |
| EBITDA | -62.47 | 133.96 | 240.62 | 162.02 | 189.37 |
| EBIT | -79.64 | 116.25 | 223.19 | 144.15 | 174.02 |
| Profit Before Tax | -33.50 | 164.90 | 255.24 | 171.76 | 207.85 |
| Net Profit | 14.33 | 121.08 | 204.24 | 150.35 | 1,219 |
| Financial Ratios | |||||
| Operating Profit Margin | -11.56% | 16.96% | 25.76% | 19.86% | 23.39% |
| Net Profit Margin | 2.65% | 15.33% | 21.86% | 18.43% | 150.57% |
| Earning Per Share (Diluted) | 1.23 | 7.15 | 11.27 | 9.02 | -4.36 |
| Dividends Per Share | 30.00 | NA | NA | NA | 30.00 |
